Oric Pharmaceuticals, Inc. · NASDAQ:ORIC
Oric Pharmaceuticals — Investor Presentation (September 2026)
49 slides from Oric Pharmaceuticals's investor presentation, September 2026
Slide 1: Company Overview
Company Overview September 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding ORIC Pharmaceuticals, Inc.’s (“ORIC”, “we”, “us”
Slide 3: ORIC Pharmaceuticals: Dedicated to Overcoming Resistance In Cancer
ORIC Pharmaceuticals: Dedicated to Overcoming Resistance In Cancer • Potential best-in-class PRC2 inhibitor for prostate cancer Validated Targets in High Unmet Need Populations • Potential best-in-class TKI for NSCLC with EGFR exon 20 insertion and EGFR atypical mutations • Rinzimetostat: first Phas
Slide 4: Executive Team with Expertise in Building Leading Oncology Companies
Executive Team with Expertise in Building Leading Oncology Companies Jacob Chacko, MD • Previously CFO at Ignyta (acquired by Roche), raised >$500m in capital Chief Executive Officer • TPG Capital (completed $10bn of aggregate acquisitions) and McKinsey & Company • Board member of 4D Molecular and B
Slide 5: Clinical Pipeline Focused on Advancement of Rinzimetostat and Enozertinib
Clinical Pipeline Focused on Advancement of Rinzimetostat and Enozertinib Discovery / Clinical Phase 3 Program Indication IND Enabling Phase 1/2 Pivotal / Phase 3 Collaboration Initiations P R O D U C T C AN D I D AT E S • Post-abiraterone Himalayas-1 • Combination with darolutamide Initiated Rinzim
Slide 6: Combination of Rinzimetostat + Darolutamide Compares Favorably to Competitor PRC2 Combination and to AR Inhibitor Monotherapy
Combination of Rinzimetostat + Darolutamide Compares Favorably to Competitor PRC2 Combination and to AR Inhibitor Monotherapy In Post-Abiraterone mCRPC Rinzimetostat Dose Optimization Update (March 2026) Mevrometostat 1250 mg BID Rinzimetostat 400 mg QD Enzalutamide Fasted + Enzalutamide + Darolutam
Slide 7: Enozertinib Phase 1b Data Establishes Potential Best-in-Class Profile in EGFR Exon 20 and PACC Mutated NSCLC
Enozertinib Phase 1b Data Establishes Potential Best-in-Class Profile in EGFR Exon 20 and PACC Mutated NSCLC Enozertinib Updated Phase 1b Data Highlights (ESMO Asia 2025) 1L EGFR Exon 20 (Preliminary Data) 1L EGFR PACC (Preliminary Data) ORR Enozertinib 67% ORR Enozertinib 80% Treatment- Naïve (1L)
Slide 8: Both Rinzimetostat and Enozertinib Have Multibillion Dollar Commercial Opportunities in the US Alone
Both Rinzimetostat and Enozertinib Have Multibillion Dollar Commercial Opportunities in the US Alone Program Initial Focus Estimated Initial US Market Opportunity Future Development Opportunities Est. Annual mCRPC >$3.5bn Opportunity US Incidence Post-Abiraterone Annual US Incidence: 17,000 mCRPC 37
Slide 9: Rinzimetostat
Rinzimetostat Allosteric PRC2 Inhibitor
Slide 10: Rinzimetostat: Potential Best-In-Class PRC2 Inhibitor for Prostate Cancer
Rinzimetostat: Potential Best-In-Class PRC2 Inhibitor for Prostate Cancer Rinzimetostat Overview KEY LIMITATIONS of approved and investigational PRC2-directed agents • Poor in vitro and in vivo potency across preclinical prostate cancer models • Inadequate clinical drug exposures due to short half-l
Slide 11: PRC2 Plays a Pivotal Role in Transcriptional Regulation and Cancer Evolution
PRC2 Plays a Pivotal Role in Transcriptional Regulation and Cancer Evolution PRC2 Introduction PRC2 Is an Epigenetic Modifier PRC2 Is a Clinically Validated Target in Multiple Cancers • PRC2 regulates gene expression by modifying chromatin, and is Polycomb Repressive implicated in tumor evolution an
Slide 12: Rinzimetostat: Next-Generation PRC2 Inhibitor Designed for Best-in-Class Drug Properties
Rinzimetostat: Next-Generation PRC2 Inhibitor Designed for Best-in-Class Drug Properties PRC2 Inhibitor Landscape in Prostate Cancer Potential Best-in-Class CPI-1205 Tazemetostat Mevrometostat Rinzimetostat Key Features (1st gen) (1st gen) (2nd gen) (3rd gen) Superior potency vs. Cellular Potency
Slide 13: Rinzimetostat Demonstrates Superior In Vitro Potency vs. First-Gen PRC2 Inhibitors
Rinzimetostat Demonstrates Superior In Vitro Potency vs. First-Gen PRC2 Inhibitors In Vitro Potency in Prostate Cancer Cells LNCaP CWR22PC (AR-Positive LNCaP Prostate Cancer Cells) (AR+ Cells) (AR-Positive Prostate Cancer Cells) CWR22PC (AR+ Cells) 1.5 CPI-1205 1.5 CPI-1205 Tazemetostat Tazemetostat
Slide 14: PRC2 Epigenetic Dysregulation Plays a Key Mechanistic Role in Prostate Cancers Treated with AR Inhibitors
PRC2 Epigenetic Dysregulation Plays a Key Mechanistic Role During the Progressive Reprogramming of Prostate Cancers Treated with AR Inhibitors PRC2 Role in Prostate Cancer AR Dependent Prostate Cancer AR Independent Prostate Cancer • Prostate cancer cells evade therapies by cellular reprogramming to
Slide 15: Rinzimetostat Increases Progression-Free Survival in Combination with Darolutamide in Xenograft Tumors
Rinzimetostat Increases Progression-Free Survival in Combination with Darolutamide in Prostate Cancer Xenograft Tumors Progression-Free Survival in Prostate Cancer Xenografts CRPC Model CSPC Model 100 Rinzimetostat + 100 Rinzimetostat + Darolutamide Darolutamide Progression-Free Survival (%) Progres
Slide 16: Mevrometostat Randomized Data Provides Clinical Validation of PRC2 Inhibitor and AR Inhibitor Combination
Mevrometostat Randomized Data Provides Clinical Validation of the Combination of PRC2 Inhibitor and AR Inhibitor in Prostate Cancer Mevrometostat Plus Enzalutamide Randomized Dose Expansion Results (ASCO GU 2025) • All patients previously treated with abiraterone and 44% previously treated with chem
Slide 17: Rinzimetostat Is Being Explored in Combination with Darolutamide and Apalutamide in Metastatic CRPC
Rinzimetostat Is Being Explored in Combination with Darolutamide and Apalutamide in Metastatic CRPC Phase 1b, Multicenter, Open-Label Trial (in Collaboration with Bayer and Johnson & Johnson) Rinzimetostat Combination Dose Exploration Rinzimetostat Combination Dose Optimization March 2026 Update Key
Slide 18: Rinzimetostat plus Darolutamide Continues to Demonstrate Strong Clinical Activity in Post-Abiraterone mCRPC
Rinzimetostat in Combination with Darolutamide Continues to Demonstrate Strong Clinical Activity in Post-Abiraterone mCRPC Patients PSA Response Data of Rinzimetostat 400 mg QD Plus Darolutamide 50 * * * Response Unconfirmed Confirmed PSA50 7/15 (47%) 5/15 (33%) 25 PSA90 2/15 (13%) 1/15 (7%) Best %
Slide 19: Rinzimetostat plus Darolutamide Demonstrates Impressive ctDNA Molecular Response
Rinzimetostat in Combination with Darolutamide Demonstrates Impressive ctDNA Molecular Response in Post-Abiraterone mCRPC Patients ctDNA Molecular Response Data of Rinzimetostat 400 mg QD Plus Darolutamide 50 MR50 10/14 (71%) MR90 4/14 (29%) Best % Change in ctDNA Fraction from Baseline 25 50 50 50
Slide 20: Radiographic Progression-Free Survival Data Are Immature, but Early Landmark Analyses Are Promising
Radiographic Progression-Free Survival Data Are Immature, but Early Landmark Analyses Are Promising in Post-Abiraterone mCRPC Patients Rinzimetostat 400 mg QD Plus Darolutamide Dose Optimization: Time on Treatment Prior Treatments Abi + IO + R Abi + IO + P + O Abi + D Abi + D + R Abi + D Abi Abi + I
Slide 21: Rinzimetostat 400 mg QD in Combination with Darolutamide Has been Generally Well Tolerated
Rinzimetostat 400 mg QD in Combination with Darolutamide Has been Generally Well Tolerated in Post-Abiraterone mCRPC Patients TEAEs Attributed to Rinzimetostat Plus Darolutamide (≥10% Total Incidence) Rinzimetostat 400 mg QD + Darolutamide Post-Abiraterone mCRPC (n=18) Adverse Events: Preferred Term
Slide 22: Rinzimetostat plus Darolutamide Demonstrates a Clearly Differentiated Safety Profile
Rinzimetostat in Combination with Darolutamide in Post-Abiraterone mCRPC Demonstrates a Clearly Differentiated Safety Profile Rinzimetostat Adverse Event Comparison to Mevrometostat Mevrometostat 1250 mg BID Rinzimetostat 400 mg QD Mevrometostat 875 mg BID Rinzimetostat 400 mg QD (Fasted) + Enzaluta
Slide 23: Rinzimetostat Demonstrates Competitive Early Landmark rPFS with a Highly Differentiated Safety Profile
Rinzimetostat Demonstrates Competitive Early Landmark rPFS in Post- Abiraterone mCRPC and Does So with a Highly Differentiated Safety Profile Landmark rPFS and Safety Benchmark Comparisons Median Grade ≥3 Dose Reductions / 3-Month rPFS 4-Month rPFS 5-Month rPFS Follow-up TRAEs Discontinuations Mevro
Slide 24: Himalayas-1: Global Phase 3 Trial of Rinzimetostat in Combination with Darolutamide
Himalayas-1: Global Phase 3 Trial of Rinzimetostat in Combination with Darolutamide in Patients with mCRPC Previously Treated with Abiraterone Rinzimetostat Global Phase 3 mCRPC Trial Rinzimetostat + • Primary Endpoint: • Patients with Darolutamide mCRPC ─ Radiographic progression-free survival (rPF
Slide 25: Rinzimetostat Is Initially Pursuing a Significant Addressable Market in Post-Abiraterone mCRPC
Rinzimetostat Is Initially Pursuing a Significant Addressable Market in Post- Abiraterone mCRPC Rinzimetostat Total Addressable Market in Post-Abiraterone mCRPC Total Addressable Market in Post-Abiraterone mCRPC Potential Rinzimetostat Share US Annual Incidence Best-In-Disease Safety and Efficacy Pr
Slide 26: PRC2 Inhibitors Have the Potential to Expand the ARPI Market
PRC2 Inhibitors Have the Potential to Expand the ARPI Market, which Currently Represents $11B and Growing Despite Significant Generic Usage Worldwide Sales and Market Share for Androgen Receptor Pathway Inhibitors Worldwide Sales (2025) Market Share in Major Markets (2024) ~$12.6B (+19% YoY) Nubeqa
Slide 27: Rinzimetostat Is Being Explored in Other Patient Populations, Including Post-AR Inhibitor mCRPC
Rinzimetostat Is Being Explored in Other Patient Populations that Could Form the Basis of Future Phase 3 Trials, Including Post-AR Inhibitor mCRPC Rinzimetostat 400 mg QD Plus Darolutamide in Post-ARi mCRPC: Time on Treatment Rinzimetostat 400 mg QD + Darolutamide Landmark % rPFS (Median Follow-up o
Slide 28: PRC2 Inhibitors Are Associated with Significant rPFS in Post-AR Inhibitor mCRPC
PRC2 Inhibitors Are Associated with Significant Radiographic Progression-Free Survival in Post-AR Inhibitor mCRPC, Comparing Favorably to Available Therapies Therapies for 1L+ mCRPC (Post-AR Inhibitor) Treatment Status 5-Month rPFS Median rPFS (months) Enzalutamide (Xtandi®) Approved N/A N/A Abirate
Slide 29: Rinzimetostat Commercial Opportunity Is Significant in Each Segment of the Prostate Cancer Treatment Continuum
Rinzimetostat Commercial Opportunity Is Significant in Each Segment of the Prostate Cancer Treatment Continuum PRC2 Inhibitor Commercial Opportunity in Prostate Cancer (US Only) mCRPC nmCSPC mCSPC nmCRPC ARPI-Naïve Prior Abiraterone Prior AR Inhibitor Initial Focus US Incidence 118,000 33,000 12,000
Slide 30: Rinzimetostat Has the Potential to Address Multiple Large Market Opportunities in Prostate Cancer
Rinzimetostat Has the Potential to Address Multiple Large Market Opportunities in Prostate Cancer, with Several Development Opportunities in Other Solid Tumors Potential Rinzimetostat Commercial Opportunity (US Only) Future Development Opportunities 90,000 >$10 billion US Est. Annual 80,000 opportun
Slide 31: Enozertinib
Enozertinib Brain-Penetrant EGFR Inhibitor
Slide 32: Enozertinib: Potential Best-in-Class TKI for EGFR Exon 20 and EGFR Atypical NSCLC
Enozertinib: Potential Best-in-Class TKI for EGFR Exon 20 and EGFR Atypical NSCLC Enozertinib Overview KEY LIMITATIONS of approved and investigational agents • Lack of CNS activity: ~50% of patients develop brain metastases and derive limited benefit with non-CNS-active drugs • Tolerability issues:
Slide 33: High Burden of CNS Disease in NSCLC Patients with EGFR Mutations
High Burden of CNS Disease in NSCLC Patients with EGFR Mutations Leads to Disease Progression and Limited Survival with Current Therapies Initial Diagnosis Disease Progression on Treatment CNS Disease Highly Prevalent in EGFR ~50% of patients eventually develop ~30% of patients have known brain meta
Slide 34: Enozertinib Was Designed to Selectively Target EGFR with High Potency Against Exon 20 and Atypical Mutations
Enozertinib Was Designed to Selectively Target EGFR with High Potency Against Exon 20 and Atypical Mutations Kinome Selectivity Comparison Enozertinib Zipalertinib Firmonertinib Silevertinib Off-target Wildtype Kinases Inhibited ≥80% at 1 µM Enozertinib Zipalertinib Firmonertinib Silevertinib 0 7 4
Slide 35: Phase 1b Trial of Enozertinib in NSCLC Patients
Phase 1b Trial of Enozertinib in NSCLC Patients Phase 1b, Multicenter, Open-Label Trial Monotherapy Key Eligibility • Advanced NSCLC EGFR Combination with SC amivantamab (1) exon 20 ─ EGFR exon 20 ─ EGFR atypical Combination with chemotherapy • Untreated, stable, asymptomatic brain metastases allowe
Slide 36: Enozertinib Phase 1b Data Establishes Potential Best-in-Class Profile in EGFR Exon 20 and PACC Mutated NSCLC
Enozertinib Phase 1b Data Establishes Potential Best-in-Class Profile in EGFR Exon 20 and PACC Mutated NSCLC Enozertinib Updated Phase 1b Data Highlights (ESMO Asia 2025) 1L EGFR Exon 20 (Preliminary Data) 1L EGFR PACC (Preliminary Data) ORR Enozertinib 67% ORR Enozertinib 80% Treatment- Naïve (1L)
Slide 37: Enozertinib Has Been Generally Well Tolerated Despite Less Stringent Enrollment Criteria for Baseline CNS Disease
Enozertinib Has Been Generally Well Tolerated Despite Less Stringent Enrollment Criteria for Baseline CNS Disease 1L EGFR exon 20 NSCLC Treatment-Related Adverse Events (TRAEs) in ≥20% of Patients 80 mg 120 mg 80 mg 120 mg Event, n (%) Event, n (%) (n=18) (n=15) (n=18) (n=15) TRAEs Grade ≥3 4 (22) 9
Slide 38: Enozertinib Achieved Strong Antitumor Activity, Including in Patients with CNS Disease at Baseline
Enozertinib Achieved Strong Antitumor Activity, Including in Patients with CNS Disease at Baseline 1L EGFR exon 20 NSCLC Best % Change in Lesions Systemic Objective Response Rate in Patients Receiving 120 mg Dose (n=15) Change From Baseline in Target Lesions, % 120 mg 20 Evaluable Population (1) (n=
Slide 39: Enozertinib Achieved Strong CNS Antitumor Activity as Measured by BICR-RANO
Enozertinib Achieved Strong CNS Antitumor Activity as Measured by BICR-RANO 1L EGFR exon 20 NSCLC Best % Change in CNS Lesions CNS Response† 120 mg in Patients Receiving 120 mg Dose (n=7) (n=7) (1) Change From Baseline in Target Lesions, % Best ORR,‡ % [95% CI] 71 [29, 96] 20 Confirmed ORR, % [95% C
Slide 40: Complete Intracranial and Partial Systemic Responses in a Treatment-Naïve EGFR Exon 20 Mutant NSCLC Patient
Complete Intracranial and Partial Systemic Responses in a Treatment-Naïve EGFR Exon 20 Mutant NSCLC Patient With Active CNS Metastases Patient: 60-year-old female Prior Therapy: None CNS Metastases at Baseline: 5 active non-target lesions (no prior radiation or surgery) Enozertinib Dose: 120 mg oral
Slide 41: Tumor Responses on Enozertinib Were Generally Achieved Early and the Vast Majority of Patients Remain on Treatment
Tumor Responses on Enozertinib Were Generally Achieved Early and the Vast Majority of Patients Remain on Treatment 1L EGFR exon 20 NSCLC • Initial cohort of efficacy evaluable patients were treated at 120 mg; given 80% dose reduction rate, most patients effectively received 80 mg • Subsequent cohort
Slide 42: Early Enozertinib Data in 1L EGFR PACC Patients Demonstrated Impressive Antitumor Activity
Early Enozertinib Data in 1L EGFR PACC Patients Demonstrated Impressive Antitumor Activity, Including in Patients with CNS Disease at Baseline 1L EGFR PACC NSCLC Best % Change in Lesions 40 in Patients Receiving 80 mg Dose (n=10) Change From Baseline in Target Lesions, % 80 mg Preliminary Response A
Slide 43: Early Enozertinib Data in 1L EGFR PACC Patients Demonstrated Strong CNS Antitumor Activity
Early Enozertinib Data in 1L EGFR PACC Patients Demonstrated Strong CNS Antitumor Activity 1L EGFR PACC NSCLC 80 mg Best % Change in CNS Lesions Preliminary CNS Response 40 (n=5) (1) in Patients Receiving 80 mg Dose (n=5) Change From Baseline in Target Lesions, % Best ORR,‡ % 80 20 Complete response
Slide 44: Partial Intracranial and Systemic Responses in a Treatment-Naïve EGFR PACC Mutant NSCLC Patient
Partial Intracranial and Systemic Responses in a Treatment-Naïve EGFR PACC Mutant NSCLC Patient with Active CNS Disease Patient: 67-year-old male PACC Mutation: G719A Prior Therapy: None CNS Metastases at Baseline: 1 target lesion Baseline BOR Timepoint (no prior radiation or surgery) Enozertinib Do
Slide 45: Enozertinib Development Is Focused on First-Line NSCLC Patients with EGFR Exon 20 and EGFR Atypical Mutations
Enozertinib Development Is Focused on First-Line NSCLC Patients with EGFR Exon 20 and EGFR Atypical Mutations Enozertinib Next Steps 2026 2027+ 1L EGFR Exon 20 Monotherapy 1L EGFR Exon 20 Ongoing Combination with SC amivantamab (1) Phase 1b Trials 1L EGFR Exon 20 Combination with chemotherapy 1L EGF
Slide 46: Enozertinib Is Pursuing a Significant Commercial Opportunity Across Patient Populations that Lack an Approved CNS Active Agent
Enozertinib Is Pursuing a Significant Commercial Opportunity Across Patient Populations that Lack an Approved CNS Active Agent Potential Enozertinib Commercial Opportunity (US Only) 12,000 >$2.5 billion US opportunity • ~10,000 patients (~5% of NSCLC) diagnosed annually 10,000 Estimated Annual Incid
Slide 47: Key Takeaways
Key Takeaways
Slide 48: Clinical Pipeline Focused on Advancement of Rinzimetostat and Enozertinib
Clinical Pipeline Focused on Advancement of Rinzimetostat and Enozertinib Discovery / Clinical Phase 3 Program Indication IND Enabling Phase 1/2 Pivotal / Phase 3 Collaboration Initiations P R O D U C T C AN D I D AT E S • Post-abiraterone Himalayas-1 • Combination with darolutamide Initiated Rinzim
Slide 49: ORIC Pharmaceuticals: Dedicated to Overcoming Resistance In Cancer
ORIC Pharmaceuticals: Dedicated to Overcoming Resistance In Cancer • Potential best-in-class PRC2 inhibitor for prostate cancer Validated Targets in High Unmet Need Populations • Potential best-in-class TKI for NSCLC with EGFR exon 20 insertion and EGFR atypical mutations • Rinzimetostat: first Phas
ORIC Pharmaceuticals — Investor Presentation (September 2026) on 6ix